Enlivex Therapeutics announced that the U.S. Patent and Trademark Office issued a new patent, number US 11,883,429, covering Allocetra, the Company’s immunotherapy product candidate. The new patent is expected to provide added intellectual property protection in the United States for the product’s composition and manufacturing method.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ENLV:
- Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
- Enlivex Therapeutics receives IMOH regulatory authorization
- Biotech Alert: Searches spiking for these stocks today
- Enlivex Therapeutics completes enrollment in Phase II trial of Allocetra
